- Vouliez-vous dire
- pathogenicity, vaccines
Résultats de la recherche - 48 results
Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
Publication Type: Peer reviewed scientific article Authors: Ingrao, Fiona; Ngabirano, Eva; Rauw, Fabienne; Dauphin, Gwenaëlle; Bénédicte Lambrecht * Source: Vaccine (2024) Abstract: The application ...
Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial.
immunogenicity of the most common travellers’ vaccine hepatitis A (HepA) and the pneumococcal conjugate vaccine (PCV) increasingly used both at home and before travel. METHODS: Volunteers aged ≥18 years (n = 305) ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
comparable antibody responses to the full dose in people <55 years. Here, we report the safety and immunogenicity of a fractional dose regimen of the BNT162 b2 vaccine. REDU- VAC is a participant-blinded, ...
Immunogenicity and one-year boostability of a 3-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-Centre clinical trial.
immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the one-year boostability of a 3-dose rabies pre-exposure prophylaxis (PrEP) ...
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.
factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162 b2 vaccine. RESULTS: C-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory ...
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
Viral Biomarkers BNT162 Vaccine COVID-19 Vaccines Humans Immunity, Humoral Immunization Schedule Immunization, Secondary Immunogenicity, Vaccine Neoplasms Prospective Studies Risk Factors Time Factors ...
A Comparative Immunogenicity and Safety Trial of Two Different Schedules of Single-visit Intradermal Rabies Post-exposure Vaccination Following a Single-visit Pre-exposure Vaccination.
E Bottieau Source: Clin Infect Dis (2018) Abstract: BACKGROUND: Effective and safe single-visit rabies vaccination for pre- and post-exposure prophylaxis (PrEP and PEP) could substantially simplify rabies ...
Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days.
result in wider acceptance. Methods: We conducted a non-inferiority trial in 500 healthy adults comparing the safety and immunogenicity of a two-visit (day 0 and day 7) intradermal (ID) primary vaccination ...
Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review.
Rupprecht, Charles E; Schumacher, Caroline; Slate, Dennis; Yakobson, Boris; Wohlers, Anne; Lankau, Emily W Source: Vet Res, Volume 48, Issue 1 (2017) Keywords: oral vaccination Rabies raboral Vaccinia wildlife ...
Tetravac/Pentavac vaccines: follow-up on the aP immunogenicity assay situation
European Directorate for the Quality of Medicines & HealthCare (EDQM),Council of Europe, NA (2016) Keywords: Follow up FOLLOW-UP meeting ON situation vaccine vaccines Health Topics: Effectiveness and ...